Daniel Iosifescu
Professor of Psychiatry
Data updated
Research Footprint
Daniel Iosifescu appears in 12 tracked papers (2012–2022), most studied alongside Ketamine, Esketamine and Placebo, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Most-cited paper: Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial (1200 citations).
Frequent co-authors: James Murrough, Sanjay Mathew and Dennis Charney.
Publication Landscape
How the 12 papers Blossom tracks for Daniel Iosifescu line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Daniel Iosifescu's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 12 of 12 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Daniel Iosifescu publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Daniel Iosifescu publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Daniel V. Iosifescu is a clinician‑researcher in psychiatry whose work focuses on rapid‑acting antidepressant treatments and the biological mechanisms underlying treatment‑resistant mood disorders. He has played a central role in multi‑site randomized controlled trials evaluating the antidepressant efficacy of ketamine in treatment‑resistant major depressive disorder, and in secondary studies that examine differential effects in anxious versus non‑anxious depression. His clinical trial work includes systematic assessment of symptomatic outcomes alongside careful characterisation of cognitive effects and safety profiles.
In parallel with clinical trials, Iosifescu has contributed to translational investigations probing neural and peripheral biomarkers of response. His publications include studies of ketamine's modulation of neural responses to emotional perception, neurocognitive sequelae and their relationship to antidepressant benefit, and altered peripheral immune signatures that correlate with and may predict treatment outcome. Collectively his work aims to refine patient selection, clarify mechanisms of action for rapid‑acting therapies, and inform safer, more personalised approaches to treating refractory mood disorders.
Key Impact
Noted for clinical and translational research on ketamine for treatment‑resistant depression, integrating neurocognitive, neuroimaging and immunological biomarkers to predict and understand treatment response.
Collaboration Network
25 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Daniel Iosifescu's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Daniel Iosifescu is associated with.
New York University
academicThe Center for Psychedelic Medicine at NYU Langone Health is directed by Dr. Michael Bogenschutz and performs health-focused research across the translational spectrum, from basic science to large-phase clinical trials. The center has three transdisciplinary areas of focus: psychiatry, medicine, and preclinical research. Currently, the team is actively investigating clinical applications for various psychedelic compounds, leading robust studies on psilocybin-assisted therapy for alcohol use disorder, major depression, and advanced cancer-related psychiatric distress.
View stakeholder →Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai in New York hosts the Parsons Research Center for Psychedelic Healing, founded by Rachel Yehuda, a psychiatrist known for three decades of work on PTSD and the biology of trauma. The centre grew out of a 2021 gift from the Bob and Renee Parsons Foundation and was expanded and renamed in 2024 with further funding and a purpose-built facility in Upper Manhattan. Working closely with the James J. Peters VA Medical Center in the Bronx, its researchers test MDMA-assisted therapy for veterans with PTSD and psilocybin for civilians, and are developing protocols for delivering MDMA within group psychotherapy. The programme pairs clinical trials with training designed to prepare therapists for supervised psychedelic-assisted care.
View stakeholder →Massachusetts General Hospital
hospitalThe Center for the Neuroscience of Psychedelics aims to better understand how psychedelics can be used to improve the treatment of mental illnesses. The core mission of the center is to understand exactly how psychedelics enhance the brain's capacity for change—or neuroplasticity—to optimize current treatments and render the term treatment resistant obsolete.
View stakeholder →National Institute of Mental Health (NIMH)
governmentU.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
View stakeholder →Mount Sinai
hospitalThe Center for Psychedelic Psychotherapy and Trauma Research located at Mount Sinai and the James J. Peters Department of Veterans Affairs examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms. The Parsons Research Center for Psychedelic Healing has also recently opened at the Icahn School of Medicine at Mount Sinai.
View stakeholder →